Common use of NOVARTIS RIGHTS TO LICENSE BACK Clause in Contracts

NOVARTIS RIGHTS TO LICENSE BACK. UP COMPOUNDS. Anytime prior to the expiry of the Lead Period with respect a particular Drug Product Candidate, NOVARTIS may also, by paying in each case the Back-up Election Fee provided under Section 6.1 of the this Agreement, exercise its Development Election with respect to any one or more Back-up Compounds associated with that Drug Product Candidate, provided that Drug Product Candidate, or a Back-up Compound selected pursuant to the provisions of Section 7.2 above, is still in active development. Any such Back-up Compound for which NOVARTIS has exercised its Development Election under Section 7.4 shall become a "Drug Product Candidate Back-up Candidate" subject to the terms and conditions of this Agreement.

NOVARTIS RIGHTS TO LICENSE BACK. UP COMPOUNDS. Anytime prior to the expiry of the Lead Period with respect a particular Drug Product Candidate, NOVARTIS may also, by paying in each case the Back-up Election Fee provided under Section 6.1 of the this License Agreement, exercise its Development Election with respect to any one or more Back-up Compounds associated with that Drug Product Candidate, provided that Drug Product Candidate, or a Back-up Compound selected pursuant to the provisions of Section 7.2 subsection (b) above, is still in active development. Any such Back-up Compound for which NOVARTIS has exercised its Development Election under Section 7.4 this subsection (d) shall become a "Drug Product Candidate Back-up Candidate" subject to the terms and conditions of this the License Agreement.

NOVARTIS RIGHTS TO LICENSE BACK. UP COMPOUNDS. Anytime prior to the expiry of the Lead Period with respect a particular Drug Product Candidate, NOVARTIS may also, by paying in each case the Back-up Election Fee provided under Section 6.1 of the this License Agreement, exercise its Development Election with respect to any one or more Back-up Compounds associated with that Drug Product Candidate, provided that Drug Product Candidate, or a Back-up Compound selected pursuant to the provisions of Section 7.2 subsection (b) above, is still in active development. Any such Back-up Compound for which NOVARTIS has exercised its CONFIDENTIAL TREATMENT REQUESTED Development Election under Section 7.4 this subsection (d) shall become a "Drug Product Candidate Back-up Candidate" subject to the terms and conditions of this the License Agreement.